PMID: 8943902Dec 1, 1996Paper

Recombinant factor IX secreted by transduced human keratinocytes is biologically active

British Journal of Haematology
A J GerrardG G Brownlee

Abstract

We have been investigating the use of human keratinocytes as potential target cells for gene therapy for haemophilia B, with the aim of curing haemophilia by means of a factor IX secreting skin graft. Previous studies indicated that keratinocytes might be suitable cells, although a potential problem was that the recombinant factor IX secreted by transduced keratinocytes was found to be only 40% biologically active. We now report, using an alternative assay to test for activity, that the secreted factor IX appears to be almost fully active.

Citations

Mar 28, 2001·The Journal of Gene Medicine·M K ChuahT VandenDriessche
Oct 30, 1998·Critical Reviews in Oncology/hematology·M K ChuahT VandenDriessche
Feb 15, 2002·British Journal of Haematology·K J Pasi
May 20, 2000·Biotechnology & Genetic Engineering Reviews·S BevanI A Mckay
Aug 1, 1997·The Journal of Investigative Dermatology·S M Page, G G Brownlee

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.